Cargando...
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
On July 31, 2009, the U.S. Food and Drug Administration granted approval for the use of bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA) in combination with interferon (IFN)-α2a for the treatment of patients with metastatic renal cell carcinoma. The approval was primarily based on re...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
AlphaMed Press
2010
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3227879/ https://ncbi.nlm.nih.gov/pubmed/20061402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0250 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|